Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Disease Suppression Persists With Ozanimod at 72 Weeks in MS
Brain Region-specific Alterations in the Gene Expression of Cytokines, Immune Cell Markers and Cholinergic System Components During Peripheral Endotoxin-induced Inflammation.
Immunology: A tolerant approach.
No excess of mitochondrial DNA deletions within muscle in progressive multiple sclerosis.
Multiple sclerosis.
Modelling and Prediction of 25-Hydroxyvitamin D Levels in Norwegian Relapsing-Remitting Multiple Sclerosis Patients.
Including known covariates can reduce power to detect genetic effects in case-control studies.
Evaluation of olfactory dysfunction in neurodegenerative diseases.
Limb Apraxia in Multiple Sclerosis: Prevalence and Impact on Manual Dexterity and Activities of Daily Living.
Cerebrospinal fluid anti-whole myelin antibodies are not correlated to magnetic resonance imaging activity in multiple sclerosis.
DMDs Are an Essential Issue But Are They the Only Issue in MS Treatment?
The spectrum of MOG autoantibody-associated demyelinating diseases.
Genetics of primary progressive multiple sclerosis.
FDA approves first oral drug to reduce MS relapses
About Tysabri
A pilot randomised controlled trial of an Internet-based cognitive behavioural therapy self-management programme (MS Invigor8) for multiple sclerosis fatigue.
Scrub typhus with longitudinally extensive transverse myelitis.
Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis.
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.
Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis.
The genetics of multiple sclerosis.
Cbl-b-deficient mice express alterations in trafficking-related molecules but retain sensitivity to the multiple sclerosis therapeutic agent, FTY720.
Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells.
Obstructive sleep apnea and fatigue in patients with multiple sclerosis.
Reliability of a cognitive endpoint for use in a multiple sclerosis pharmaceutical trial.

Pages